Clinical Trial

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-04-14; most recent amendment 2026-06-06.
Status change: Recruiting → Active, Not Recruiting 2025-08-27
Status change: Not Yet Recruiting → Recruiting 2022-06-17
Trial Details
NCT Number NCT05336786
Lead Sponsor Thomas Jefferson University
Collaborators: National Cancer Institute (NCI)
Conditions Prostate Carcinoma
Enrollment 70 participants
Start Date 2022-06-15
Primary Completion 2025-05-26 (estimated)
Study Completion 2026-05-26 (estimated)
Updated on ClinicalTrials.gov 2025-09-04